Poster Session:
052. HIV
Friday, October 30, 2009: 12:30 PM-2:00 PM
Room: Poster Hall A

Tracks: HIV

Presentations:

12:30 PM
264
HIV-1 Evolution and Drug Resistance Among Patients Receiving Antiretroviral Therapy (ART) in San Mateo County, California, 1997-2006
Sudeb Dalai, MS ; Jonathan Dyal, BA ; Dennis Israelski, MD ; Seble Kassaye, MD ; David Katzenstein, MD ; Vivian Levy, MD ; Keyan Salari, BS

12:30 PM
265
Emergence and Risk Factors of HIV-1 Drug Resistance in Antiretroviral-naïve Patients in Thailand
Wasun Chantratita, PhD ; Sasisopin Kiertiburanakul, MD, MHS ; Bucha Piyavong, BSc ; Chonlaphat Sukasem, Ph.D. ; Somnuek Sungkanuparph, MD

12:30 PM
266
Drug Resistance and Susceptibility Genotype from Proviral DNA vs. Circulating RNA Among Subtype B HIV-1 Infected Subjects
Maya Balamane, BS ; Sudeb Dalai, MS ; Dennis Israelski, MD ; Elizabeth Johnston, PhD ; David Katzenstein, MD ; Jeffrey Klausner, MD MPH ; Elizabeth McKean, MS ; Hyoung-Shik Shin, MD PhD

12:30 PM
267
A Randomized Trial of Routine HIV-1 Viral Load Monitoring of Antiretroviral Therapy in Zambia: Implementation, Baseline Cohort, and Early Findings
Benjamin Chi, MD, MSc ; John Koethe, MD ; Michael S. Saag, MD ; Jeff Stringer, MD ; Andrew Westfall, MS ; Isaac Zulu, MD, MPH

12:30 PM
268
The TaqMan Cometh: Hidden Costs of a New Viral Load Assay
Jeffrey Burkhardt, PhD, FHFMA ; Michael J. Mugavero, MD, MHSc ; James Raper, DSN, CRNP, JD, FAANP ; Michael Saag, MD ; Joseph Schumacher, PhD ; Amanda Willig, MS ; James H. Willig, MD, MSPH

12:30 PM
269
Pharmacokinetics (PK) of Humanized, Anti-CCR5 Monoclonal Antibody PRO 140 in Treatment Naïve Subjects Infected with HIV-1
Daniel Berger, MD ; Paul D'Ambrosio, PhD ; Carl Fichtenbaum, MD ; Stephen Morris, MD PhD ; Barry Zingman, MD

12:30 PM
270
Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR) Pharmacokinetics (PK) in the Cervicovaginal Fluid (CVF) and Blood Plasma (BP) of HIV-Infected Women Enrolled in the GRACE Study
Ronald Falcon, MD ; Steven Jennings, BSc ; Angela Kashuba, BScPhm, PharmD, DABCP ; Joseph Mrus, MD, MSc ; Kristine Patterson, MD ; Naser Rezk, PhD

12:30 PM
272
Steady state pharmacokinetics (PK) of atazanavir/ritonavir (ATV/r) during pregnancy in HIV+ women
Richard Bertz, PhD ; Michael Child, BS ; Timothy Eley, PhD ; Awny Farajallah, MD ; Tong Guo, MS ; Shanmei Liao, PhD ; Donnie McGrath, MD ; Heather Sevinsky, MS ; Eric Vandeloise, BS ; Yonghua Wang, PhD ; Victoria Wirtz, MS

12:30 PM
273
The Impact of Background Regimen on Virological Response to Etravirine in Treatment-Experienced, HIV-1-Infected Patients: Pooled 96-week Analysis of DUET-1 and DUET-2
Beatriz Grinsztejn, MD, PhD ; Richard Haubrich, MD ; José Valdez Madruga, MD ; Steven Nijs, MS ; Johan Vingerhoets, PhD ; James Witek, MD

12:30 PM
274
Comparative Effectiveness of Regimen Durability and 48-week Virologic Suppression among 3-class Experienced HIV-infected Patients in a US Clinical Cohort
Inmaculada Aban, PhD ; Guy De La Rosa, MD ; Lori DeLaitsch, MPH ; James McKinnell, MD ; Joseph Mrus, MD, MSc ; Michael J. Mugavero, MD, MHSc ; Christa Nevin, MSPH ; James Raper, DSN, CRNP, JD, FAANP ; Michael Saag, MD ; James H. Willig, MD, MSPH ; Jiatao Ye, PhD

12:30 PM
275
Safety and Efficacy of Unboosted Atazanavir (ATV)-based Regimens in Treatment-Naive Patients by Gender
Judith Absalon, MD ; Kristy Grimm, PharmD ; Tony Hosey, PharmD ; Kim Nguyen, PharmD ; Kathleen Squires, MD

12:30 PM
276
144-Week Efficacy and Safety of Raltegravir (RAL) in Treatment-Experienced Patients
Joseph J. Eron, MD ; Jose Gatell, MD ; Charles Gonzalez, MD ; Beatriz Grinsztejn, MD, PhD ; Robin Isaacs, MD, for the Protocol 005 Team ; Christine Katlama, MD ; Adriano Lazzarin ; Chengxing Lu, PHD ; Bach-Yen Nguyen, MD ; Daniel Vittecoq, MD ; Carolee Welebob, MS

12:30 PM
277
Utilization Patterns of Raltegravir within the OPERA Database
Felix Carpio, MD ; Edwin DeJesus, MD, FACP ; Douglas Dieterich, MD ; Gregory Fusco, MD, MPH ; Jennifer Fusco, BS ; Phil Lackey, MD ; Gerald Pierone, MD ; Michael Wohlfeiler, MD

12:30 PM
278
Virologic Response to Raltegravir (RAL) Salvage and Maintenance Therapy
W Jeffery Fessel, MD ; Stephen Follansbee, MD ; Michael Horberg, MD MAS ; Leo Hurley, MPH ; Daniel Klein, MD ; Tommy Liu, BS ; Soo-Yon Rhee, MS ; Robert Shafer, MD

12:30 PM
279
Tolerability in the Routine Clinical-Use of Raltegravir in a Large Veteran Cohort
Debra Benator, MD ; Angelike P. Liappis, MD ; Amy Treakle, MD

12:30 PM
280

12:30 PM
281

12:30 PM
282
Use of Protease Inhibitors and Kidney Tubular Injury without Glomerular Abnormalities in HIV-infected Patients
Atsushi Ajisawa, MD, PhD ; Minoru Ando, MD, PhD ; Akifumi Imamura, MD ; Kosaku Nitta, MD, PhD ; Akihiko Suganuma, M.D ; Ken Tsuchiya, MD, PhD ; Naoki Yanagisawa, MD

12:30 PM
283
Lactic Acidosis in a Randomized Trial of d4T- vs ddI-based First-line Therapy in HIV-infected Adults in South Africa
J Dlamini, MBBCh ; C Hadigan, MD ; P Khabo, PhD ; H Kowo, RN ; L Ledwaba, MBChB ; P Maja, BSc ; T Mokhathi, RN ; N Mokwena, MBChB ; S Orsega, NP ; M Proschan, PhD ; M Tsoku, RN

12:30 PM
284
Hepatic Safety and Tolerability of Etravirine: Pooled 96-week Analysis of DUET-1 and DUET-2
Patricia Izurieta, MD, PhD ; Adriano Lazzarin ; Steven Nijs, MS ; Mauro Schechter, MD, PhD ; William Towner, MD ; James Witek, MD

12:30 PM
285
TMC278 25mg qd Has No Effect on Corrected QT (QTc) Interval in HIV-Negative Volunteers
Katia Boven, MD ; Annemie Buelens, MSc ; Herta Crauwels, PhD ; Lorant Leopold, MD ; Marita Stevens, MD ; Rolf van Heeswijk, PhD ; Simon Vanveggel, MSc

12:30 PM
286
Clinical and Genetic Factors Influencing Severe Atazanavir-induced Hyerbilirubinemia in Korean HIV Patients; Importance of Polymorphisms at the Multidrug Resistance Gene 1
Kang Won Choe, MD ; Pyoeng Gyun Choe ; Jae Hyun Jeon, MD ; Hong Bin Kim ; Kye-Hyung Kim, MD ; Nam Joong Kim, MD, PhD ; Shinwon Lee, MD ; Myoung-don Oh, MD, PhD ; Sang-Won Park, MD ; Wan Park, MD, PhD ; Kyoung Ho Song, MD ; Na Ra Yun, MD

12:30 PM
287
Cost-Efficacy Analysis of Darunavir/r Vs. Lopinavir/r as a First-Line HIV Treatment in the United States
Anita Brogan, PhD ; Joseph Mrus, MD, MSc ; Erik Smets, MSc, MBA ; Sada Soorapanth, PhD

12:30 PM
289
The Effect of Acyclovir on CD4 Count and CD4 Percent
Slope in HIV-1/HSV-2 Co-infected Women Taking Highly Active Antiretroviral Therapy (HAART)

Angela Caliendo, MD, PhD, FIDSA ; Stacey Chapman, RN, ASN ; Susan Cu-Uvin, MD ; Allison DeLong, MS ; Jaclynn Kurpewski, BS, CLS ; Tao Liu, MS ; Jenny McManus, BS ; Ank Nijhawan, MD, MPH ; Kimberly Rapoza, BS

12:30 PM
290
Drug Resistance and Envelope Co-receptor Tropism Following Zidovudine Monotherapy in HIV-1
Maya Balamane, BS ; Elizabeth Johnston, PhD ; David Katzenstein, MD ; Hyoung-Shik Shin, MD PhD ; Nancy Shulman, MD

12:30 PM
291
Virologic Suppression on 2nd-Line Antiretroviral Therapy (ART) in a Community-Based Program in South Africa
YuChiao Chang, PhD ; Kenneth Freedberg, MD, MSc ; Julie Levison, MD, MPhil ; Elena Losina, PhD ; Catherine Orrell, MBChB, MMed ; Robin Wood, MD, PhD

12:30 PM
292
Use of Non-Recommended Antiretroviral Regimens in a Multi-Site Pediatric Cohort (2002-2006)
Allison Agwu, MD ; Jennifer Chang, BS ; Kelly Gebo, MD, MPH ; P. Todd Korthuis, MD, MPH ; Richard Rutstein, MD ; George Siberry, MD ; Stephen A. Spector, MD ; Robert Warford, NP

12:30 PM
293
CD4 Response to Antiretroviral Treatment in HIV Patients with Renal Insufficiency
Sana Akbar, MD ; Eliahu Bishburg, MD ; Shameen Khan, DO ; Suja Mathai, MD ; Sandhya Nalmas, MD ; Jihad Slim, MD

12:30 PM
294
Genital Tract Soluble Immunity: Biological Link Between HSV and HIV
Esra Fakioglu, MD ; Betsy Herold, MD ; Sarah Wilson, BS

12:30 PM
295
Neutralization of HIV-1 by Breast Milk IgG from HIV-Infected Women in Uganda
Mary Glenn Fowler, MD ; Laura Guay, MD ; Edward Janoff, MD ; Michelle McConnell, MD ; Jana Palaia, BS ; Kristina Stoermer, BA

12:30 PM
296
Cryopreservation decreases the expression of regulatory T cell markers
Carolina de la Flor, Medical Student ; Dorothy Lewis, PhD ; Giovanni Lopez, BSc ; Martin Montes, MD ; Cesar Sanchez, MD ; Sebastian Sattui, Medical Student ; A White, MD

12:30 PM
297
Optimization of Clinical Cutoffs for Determining HIV Co-Receptor Use by Population and “Deep” Sequencing Methods
P. Harrigan, PhD ; lence in HIV, Canada & Pfizer Inc, MOTIVATE Tropism Study Group. BC Centre for Excel

12:30 PM
299
Hepatitis C Virus Co-infection and Sexual Risk Behavior Are Associated with High Homocysteine Serum Level in HIV-infected Patients
Carlos Andreu, PhD ; Mari del Monte, RN ; Jose Ferrero, PhD ; Maria Ramos, PhD ; Bernardino Roca, PhD ; Manuel Roca, MS

12:30 PM
300
Proteinuria and Chronic Kidney Disease in Subjects with HIV and Hepatitis C (HCV) Co-infection and HCV mono-infection
Deborah Cotton, MD MPH ; Erika Edwards, MPH ; Shikha Garg, MD ; Timothy Heeren, PhD ; Melanie Hoenig, MD ; C. Horsburgh, MD MS ; Sheila Tumilty, BSN

12:30 PM
301
Acyclovir Does Not Change HIV-1 Set Point in HSV-2 Seropositive Persons Treated During Early HIV-1 Infection
Connie Celum, MD MPH ; Robert Coombs, MD PhD ; Susan Eshleman, MD PhD ; James Hughes, PhD ; Nina Kim, MD MS ; Robert Siliciano, MD PhD ; Anna Wald, MD, MPH, FIDSA ; Jing Wang, MS

12:30 PM
302

12:30 PM
303
The Effect of HIV on Malaria Incidence in HIV Exposed Tanzanian Infants
Said Aboud, MD, MMED ; Ronald Bosch, PhD ; Christopher Duggan, MD, MPH ; Amara Ezeamama, PhD ; Wafaie Fawzi, MD, MPH, DrPH ; Roland Kupka, PhD ; Melanie Lo, MHS ; Karim Manji, MBBS, MMED, MPH ; James Okuma, MS

12:30 PM
304
CSF Cytokines Biomarkers Predict Risk of Immune Reconstitution Inflammatory Syndrome in Ugandan Patients with HIV and Cryptococcal Meningitis
P Bohjanen, MD, PhD ; S Bonham, MD ; D Boulware, MD, MPH ; E Janoff, MD ; A Kambugu, MMed ; D Meya, MMed ; M Tabaka, BA ; D Wiesner, MS

12:30 PM
305
JC Virus-associated Central Nervous System Diseases in HIV-infected Patients in Brazil: Clinical and Laboratory Features and Associated Factors with Mortality
Maria Fink, MD ; Cláudio Pannuti, MD, PhD ; Augusto Penalva de Oliveira, MD, PhD ; Felipe Piza, MD ; José Vidal, MD, PhD

12:30 PM
306
Tuberculosis Rates among HIV-Infected Persons in New York City, 2001-2005
David Hanna, MS ; Tiffany Harris, PhD ; Chrispin Kambili, MD ; Jiehui Li, MBBS, MS ; Lisa Trieu, MPH

12:30 PM
307
Utility of Interferon-Gamma Release Assays in Diagnosing Latent Tuberculosis Infection among HIV-discordant Couples in Zambia
Susan Allen, MD ; Henry Blumberg, MD ; Elwyn Chomba, MD ; Carlos delRio, MD ; Esteban Gonzalez-Diaz, MD ; William Kilembe, MD ; Charles Mutemba, MD ; Lawrence Mwananyanda, MD ; Naasha Talati, MD ; Joyanna Wendt, MD

12:30 PM
308

12:30 PM
309
Protease Inhibitors (PI) Versus NNRTIs Based Antiretroviral Therapy in HIV/TB Co-infected Patients
Jose Bruguera, MD ; Jorge Corral, MD ; Daniel David, MD ; Oscar Garcia Messina, MD ; HIV/TB Argentine Study Group ; Claudia Leroux, MD ; Marcelo Losso, MD ; Cristina Miglioranza, MD ; Natalia Tamayo, MD ; Javier Toibaro, MD ; Guillermo Viloria, MD ; Eduardo Warley, MD

12:30 PM
310
Clinical Impact and Cost-Effectiveness of Treatment for Latent Tuberculosis in HIV+ Patients in India
Kenneth Freedberg, MD, MSc ; Nagalingswaran Kumarasamy, MD, PhD ; Elena Losina, PhD ; Kenneth Mayer, MD ; Mai Pho, MD ; C. Ponnuraja, PhD ; Callie Scott, BA ; Soumya Swaminathan, MD ; Lauren Uhler, BA ; Rochelle Walensky, MD, MPH, FIDSA

12:30 PM
312
HIV Testing in Emergency Department: A Survey of ED Providers
Anneta Golubchik, MD ; Michael Lemanski, MD ; Daniel Skiest, MD

12:30 PM
313
Are Baltimore City HIV screening programs reaching at-risk Latinos
Nadine Chen, MD, MPH ; Emily Erbelding, MD, MPH ; Kathleen Page, MD, PhD

12:30 PM
314
HIV testing in the Emergency Department: how universal is our screening?
Charles Gerardo, MD ; Charles Hicks, MD ; Mehri McKellar, MD ; Gregory Samsa, MD ; Nicholas Steinour, MD

12:30 PM
315
HIV test type choice and entrance in care in a Baltimore sexually transmitted diseases clinic
Emily Erbelding, MD, MPH ; Joyce Jones, MD, MS ; Sara Keller, MD, MPH

12:30 PM
317
The High Positive Immunoassay Confirms HIV-1 Infection and Avoids the Need of Confirmatory Tests
Joana Cortez-Mares, MD ; Rodolfo Ochoa-Jiménez, MD, MSc ; Mónica Ríos-Silva, MD, MSc ; Benjamín Trujillo-Hernandez, MD, MSc

12:30 PM
320
Factors Associated with HAART Initiation in an Open Access Cohort
Brian Agan, MD ; R. Vincent Barthel, MD ; Nancy Crum-Cianflone, MD MPH ; Anuradha Ganesan, MD ; Erica Johnson, MD ; Michael Landrum, MD ; Mollie Roediger, MS ; Amy Weintrob, MD

12:30 PM
321
Differences in National Antiretroviral Prescribing Patterns between Black and White HIV / AIDS Patients from 1996-2006
Carolyn Brown, PhD ; Christopher Frei, PharmD, MSc ; Kenneth Lawson, PhD ; Christine Oramasionwu, PharmD, MSc ; Alice Pau, PharmD, FIDSA ; Laurajo Ryan, PharmD, MSc

12:30 PM
322
Patterns of Virologic Suppression and Mortality Among Treatment-Naïve Patients Initiating Antiretroviral Therapy
Inmaculada Aban, PhD ; Jeroan Allison, MD, MSc ; Mirjam Kempf, PhD, MPH ; Ricardo La Hoz, MD ; Michael J. Mugavero, MD, MHSc ; Christa Nevin, MSPH ; James Raper, DSN, CRNP, JD, FAANP ; Michael Saag, MD ; James H. Willig, MD, MSPH ; Jiatao Ye, PhD

12:30 PM
323
Trends in Hospitalizations among HIV-Infected Persons during the Late HAART Era: What are the Impact of HAART Use and CD4 Counts?
Brian Agan, MD ; Am and the Infectious Disease Clinical Research Progr ; Robert Barthel, MD ; Nancy Crum-Cianflone, MD MPH ; Anuradha Ganesan, MD ; Greg Grandits, MS ; Michael Landrum, MD ; Amy Weintrob, MD

12:30 PM
325
All-Cause Mortality in Hospitalized HIV-Infected Patients (HIP) in Two Urban Hospitals: A Five-Year Review
Vani Gandhi, MD ; Efrain Gonzalez, MD ; Mary Clarisse Kilayko, MD ; Jong Hun Kim, MD ; George Psevdos Jr., MD ; Victoria Sharp, MD ; Sunita Singh, MD

12:30 PM
326
Impact of Renal Disease on All- Cause Mortality in Subjects with HIV and Hepatitis C (HCV) Co-infection
Caleb Bliss, MA ; Alison Coe, MA ; Deborah Cotton, MD MPH ; Erika Edwards, MPH ; Shikha Garg, MD ; Timothy Heeren, PhD ; Melanie Hoenig, MD ; C. Horsburgh, MD MS ; Sheila Tumilty, BSN

12:30 PM
327
Comparison of Survival and Clinical Outcomes between HIV-infected Patients with and without HCV Co-infection in a Resource-limited Setting where HCV Treatment is not Affordable
Jaranit Kaewkungal, PhD ; Wirach Maek-a-nantawat, MD. ; Punnee Pitisuttithum, MD ; Somnuek Sungkanuparph, MD ; Nan THAN, MD

12:30 PM
329
Trends in Mortality Rates and Causes of Death for HIV-infected Patients in Republic of Korea, 1988-2008
Pyoeng Gyun Choe ; Jae Hyun Jeon, MD ; Hong Bin Kim ; Nam Joong Kim, MD, PhD ; Myoung-don Oh, MD, PhD ; Sang-Won Park, MD, PhD ; Wan Beom Park ; Kyoung-Ho Song, MD

12:30 PM
330
Early Infectious Diseases Team Notification of HIV-infected, Hospitalized Patients Improves Antiretroviral Prescribing
Deborah Anderson, PharmD ; William Burman, MD ; Timothy Jenkins, MD ; Jessica Morris, PharmD ; Allison Sabel, MD, PhD, MPH ; Amy Trantanella, BS

12:30 PM
331
Mortality in an HIV- Infected Clinical Cohort in the Southeastern United States, 2000-2007
Gretchen Arnoczy, MD ; Joseph Eron, MD ; Jonathan Juliano, MD ; Sonia Napravnik, PhD ; Amanda Peppercorn, MD ; Becky White, MD ; David Wohl, MD

12:30 PM
332
Effect of Clinic Visit Frequency on HIV Clinical Care and Virologic Outcome
Donald Blair, MD ; Madhuchhanda Choudhary, MD ; Christopher Morrison, Medical Student

12:30 PM
333
Barriers to HAART Adherence in Patients with HIV at “Hôpital Albert Schweitzer” in Deschapelles, Haiti
Darwin Dorestan, MD ; Natalie Durandisse, MD ; Christiane Hadi, MD, MPH ; Lauren Richey, MD, MPH ; Janine VanSant, MD

12:30 PM
334
Prevalence and Predictors of Medical Appointment Non-Adherence at a Southeastern US Veterans Affairs HIV Clinic
John Baddley, MD, MSPH ; Victoria Johnson, MD, FIDSA ; Kimberly Kelly, BS ; Michael J. Mugavero, MD, MHSc

12:30 PM
335
Predictors of response in GRACE (Gender, Race And Clinical Experience)
Bruce Coate, BS, MPH ; Judith Currier, MD, MSc ; Princy N. Kumar, MD ; Joseph Mrus, MD, MSc ; on behalf of the GRACE Study Group ; Robert Ryan, MS ; Kathleen Squires, MD

12:30 PM
337
Factors Associated with Utilization of ART Amongst Hard-to-Reach HIV + Individuals in Atlanta, GA
Carlos Del Rio, MD, FIDSA ; Ekaterina Kurbatova, MD MPH PhD ; Paulina Rebolledo, MD MSc ; Richard Rothenberg, MD MPH

12:30 PM
339
Differential Adherence to Antiretroviral Therapy and Lipid-Lowering Therapy During Concomitant Use
William Burman, MD ; Vivian Cox, MD ; Edward Gardner, MD ; Moises Maravi, BS, MSc

12:30 PM
340
Feasibility of Primary HIV Care in A Thai Tertiary Care Center (TCC)
Anucha Apisarnthanarak, MD ; Thana Khawcharoenporn, MD ; Danai Kitkungvan, MD ; Panthipa Laowansiri, MD ; Linda Mundy, MD ; Somnuek Sungkanuparph, MD

12:30 PM
341
Pandemic Influenza is a Strong Motivator for Participation in Vaccine Clinical Trials among HIV-positive Canadian Adults
Curtis Cooper, MD ; David Haase, MBBS ; Beth Halperin, RN, MN ; Mathew Kiberd, BSc ; Shelly McNeil, MD ; Jason Slaunwhite, PhD(c)

12:30 PM
342
Obesity among HIV-Infected Persons: Impact of Weight on CD4 Cell Counts
Brian Agan, MD ; Am and the Infectious Disease Clinical Research Progr ; Robert Barthel, MD ; Nancy Crum-Cianflone, MD MPH ; Lynn Eberly, PhD ; Anuradha Ganesan, MD ; Michael Landrum, MD ; Mollie Roediger, MS ; Kurt Vyas, BA ; Amy Weintrob, MD

12:30 PM
343
Efficacy of Double Dose Hepatitis B Rescue Vaccination in HIV-Infected Patients
Vanessa Groce, RN ; Jong Hun Kim, MD ; George Psevdos Jr., MD ; Victoria Sharp, MD

12:30 PM
344
Predictors of Hepatitis A Vaccine Response in HIV-Infected Patients
Rabih Hallit, MD ; Humberto Jimenez, PharmD, BCPS, AAHVE ; Pan Ko, MD ; Gobuiwang Kurusa, MD ; George Perez, MD ; Jihad Slim, MD

12:30 PM
345
Addressing Anal Health in the HIV Primary Care Setting: A Disappointing Reality
Gabriel Cardenas, MPH ; Gordon Dickinson, MD ; Lisa Metsch, PhD ; Isabella Rosa-cunha, M.D.

12:30 PM
346
Frequency of Superinfecting Microorganisms in Patients Infected With Human Immunodeficiency Virus with Periodontitis
Texar Pereyra, Master degree ; Lorena Reyes Vazquez, Dentist ; Ignacio Yañez Gutierrez, Periodoncist specialist

12:30 PM
347
Prevalence of Dental Caries and Periodontal Diseases in an Urban Ryan White Funded Dental Clinic in the HAART Era
Clifford Gunthel, MD ; Judy McGUIRE, DDS ; Minh Ly Nguyen, MD, MPH ; Deepa Reddy, MD ; David Reznik, DDS ; Anitra Sumbry, MPH

12:30 PM
348
Impact of Heavy Alcohol Use on HIV Disease Progression in the Era of HAART
Shirish Barve, PhD ; Arna Davidson, NP ; Anna Huang, MD ; Rama Kapoor, MD ; Raul Nakamatsu, MD ; Paula Peyrani, MD ; Julio Ramirez, MD ; Timothy Wiemken, MPH

12:30 PM
349
Immunosuppression and Higher Viral Load Are Associated with Decreased Physical Performance among Aging HIV-Infected Persons
Mohammad Ahmed, MD, MHS ; Jack Guralnik, MD, PhD ; Gregory Kirk, MD, MPH, PhD ; Shruti Mehta, PhD, MPH ; Kushang Patel, PhD, MPH ; Megan Salter, MHS

12:30 PM
350
Frailty Among HIV-Infected Persons in an Urban Outpatient Care Setting
Yomi Agbebi, MD ; Alev Onen, BA ; Nur Onen, BSc, MBChB ; E. Overton, MD ; Enbal Shacham, MPE, PHD ; Kate Stamm, BA

12:30 PM
351
HIV -Associated Neurocognitive Impairment Remains Prevalent in the Era of HAART
Abayomi Agbebi, MD ; Onen Nur, MD ; Diana Nurutdinova, MD ; Turner Overton, MD ; Enbal Shacham, MPE, PHD ; Katelyn Stamm, Bsc

12:30 PM
352
Treatment of Depression in HIV+ Individuals
Richard Moore, MD, MHS ; Adrienne Shapiro, MSc ; Glenn Treisman, MD, PhD

12:30 PM
353
Risk Factors for Obstructive Lung Disease in a Urban Cohort of HIV-infected Patients
Kevin Fennelly, MD, MPH ; Sally Hodder, MD ; Ramanasri Kudipudi, MD ; Brimacombe Michael, PhD ; Andres Rivero, MD ; Jason Seiden, MD

12:30 PM
355
HIV-associated Lung Cancer (HIV-LC): a Multi-institutional Analysis of 77 Cases
David Aboulafia, MD ; Mark Bower, MD ; Susan Buskin, PhD ; Tim Cooley, MD ; Bruce Dezube, MD ; Gabriela D'Jaen, BA ; Erin Greco, MS ; David Henry, MD ; Nancy Neil, PhD ; Liron Pantanowitz, MD ; Justin Stebbing, MD ; Jonathan Stem, MD

12:30 PM
356
Longitudinal Assessment of Pulmonary Arterial Hypertension in Asymptomatic HIV-Infected Patients
Jason Blaylock, MD ; David Byers, MD ; Catherine Decker, MD ; MIchael Ferguson, MD ; Barnett Gibbs, MD ; Gautam Nayak, MD ; Chad Porter, MPH ; David Tribble, MD, DrPH

12:30 PM
357
Rate and Serotype Identification of GBS Colonization in a HIV + Pregnant Women Cohort in Rio de Janeiro
Plinio Berardo, MD, PhD ; Ana Botelho, BSc ; Sérgio Fracalanzza, Pharm, PhD ; Maria Isabel Gouvea, MD, MSc ; Beatriz Grinsztejn, MD, PhD ; Esau Joao, MD ; Caio Rodrigues, Pharm, MSc ; Leon Sidi, MD ; Maria José Souza, MD

12:30 PM
358
Pregnancy outcomes in a cohort of women infected with human immunodeficiency virus (HIV)
Jean Anderson, MD ; Emilia Campbell, MS ; Jessica Opoku-Anane, MS ; Adrienne Shapiro, MSc ; Hindi Stohl, MD

12:30 PM
359
Prevention of Vertical HIV Transmission at “Hôpital Albert Schweitzer” in Deschapelles, Haiti
Darwin Dorestan, MD ; Natalie Durandisse, MD ; Christiane Hadi, MD, MPH ; Lauren Richey, MD, MPH ; Janine VanSant, MD

12:30 PM
360
The Effect of Acyclovir on the Prevalence of Bacterial Vaginosis in HIV-1/HSV-2 Co-infected Women Taking Highly Active Antiretroviral Therapy (HAART)
Angela Caliendo, MD, PhD, FIDSA ; Stacey Chapman, RN, ASN ; Susan Cu-Uvin, MD ; Allison DeLong, MS ; Jaclynn Kurpewski, BS, CLS ; Tao Liu, MS ; Jenny McManus, BS ; Ank Nijhawan, MD, MPH ; Kimberly Rapoza, BS

12:30 PM
361
Prevalence of Abnormal Anal Pap Smears in a Population of HIV-Infected Women
Michael Brimacombe, PHD ; Sally Hodder, MD ; Olabisi Kuye, MD ; Helen Makinde, MD ; Natalie Roche, MD ; Shobha Swaminathan, MD

12:30 PM
362
Pregnancy Outcomes in Vertically and Behaviorally HIV-Infected Youth in a Multi-site Clinical Cohort
Allison Agwu, MD ; Kelly Gebo, MD, MPH ; Susie Jang, BA ; P Korthuis, MD, MPH ; Robert Warford, NP

12:30 PM
363
Significantly Lower Rates of HAART Utilization in HIV-1 Infected Youth vs. Adults Meeting Treatment Criteria in a Large Multisite U.S. Cohort
Allison Agwu, MD ; Jonathan Ellen, MD ; Aditya Gaur, MD ; Kelly Gebo, MD, MPH ; Richard Rutstein, MD ; George Siberry, MD ; Stephen A. Spector, MD ; Robert Warford, NP

12:30 PM
364
Factors Associated with Thrombosis in HIV-Infected Individuals
John Brooks, MD ; James Heffelfinger, MD, MPH ; Marta Juhasz, MS ; A.D. McNaghten, PhD ; Pragna Patel, MD ; Patrick Sullivan, DVM, PhD ; Andrew Voetsch, PhD

12:30 PM
365
Prevalence and Predictors of Dyslipidemia in an ARV Naïve HIV Positive Population in Tanzania
Catharina Armstrong, MD ; Wafaie Fawzie, MD, MPH, Dr PH ; Steven Grinspoon, MD ; Chalamilla Guerino, MD ; Claudia Hawkins, MD ; Enju Liu, PHD ; Marina Njelekela, MD, PHD ; James Okuma, MS ; Donna Spiegelman, PHD

12:30 PM
366
Dyslipidemia among Latin American HIV-Infected Patients: The RAPID Study Group
Robinson Cabello, MD ; Isabel Casseti, MD ; Beatriz Grinsztejn, MD ; William Lenis, MD ; Jose Piloto, MD ; Yajaira Roldan, MD

12:30 PM
367
Predicted Risks for Coronary Heart Disease (CHD) during Boosted Protease Inhibitor (bPI) Therapy
Jeffrey Miller, MD ; Karam Mounzer, MD ; Linda Mundy, MD ; Roula Qaqish, Pharm D ; Richard Rode, PhD

12:30 PM
368
Prevalence of Peripheral Arterial Disease in an HIV-Infected Population
Maria Chini, MD ; Florina Dutsu, MD ; Marios Lazanas, MD ; Nikos Mangafas, MD ; Alexandros Tsakiris, MD ; Nikos Tsogas, MD

12:30 PM
369
Longitudinal Assessment of Cardiac Diastolic Function in HIV-Infected Patients
Jason Blaylock, MD ; David Byers, MD ; Catherine Decker, MD ; MIchael Ferguson, MD ; Barnett Gibbs, MD ; Gautam Nayak, MD ; Chad Porter, MPH ; David Tribble, MD, DrPH

12:30 PM
370

12:30 PM
373
Sexually Transmitted Infections in Public Housing Residents Scheduled for Relocation
Loida Bonney, MD ; Angela Caliendo, MD, PhD, FIDSA ; Hannah Cooper, ScD ; Carlos Del Rio, MD, FIDSA ; Tanisha Grimes, PhD, MPH ; Richard Rothenberg, MD MPH

12:30 PM
374
Gonorrhea and Chlamydia Testing Rates of HIV-Infected Men after Enrollment into HIV Care
Stephen Berry, MD ; Kelly Gebo, MD, MPH ; Khalil Ghanem, MD, PhD, FIDSA ; Richard Moore, MD, MHS ; Kathleen Page, MD, PhD ; Chloe Thio, MD, FIDSA

CME Credits:

ACPE Credits:

ACPE Number: NO CPE CREDIT


See more of: Poster Session